In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 25 of 427

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]	Technology appraisal guidance	12 February 2025
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]	Technology appraisal guidance	TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]	Technology appraisal guidance	TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533	Technology appraisal guidance	TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]	Technology appraisal guidance	TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance	20 August 2025
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339	Technology appraisal guidance	2 July 2025
Advanced breast cancer: diagnosis and management (Partial update)	NICE guideline	TBC
Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension	Interventional procedures guidance	5 February 2025
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]	Technology appraisal guidance	13 November 2024
ALXN1840 for treating Wilson disease TS ID 9950	Technology appraisal guidance	TBC
Alzheimer's disease (early) - gantenerumab [ID6142]	Technology appraisal guidance	TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	30 April 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256	Technology appraisal guidance	20 August 2025
Amyotrophic lateral sclerosis - SAR443820 [ID6386]	Technology appraisal guidance	TBC
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]	Technology appraisal guidance	11 December 2024
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway	Health technology evaluation	19 December 2024
Artificial intelligence software to help detect and characterise colorectal polyps	Diagnostics guidance	TBC
Artificial intelligence technologies to help detect fractures on X-rays in urgent care	Health technology evaluation	14 January 2025
Asthma: diagnosis, monitoring and chronic asthma management	NICE guideline	27 November 2024
Asunercept for treating glioblastoma [1301]	Technology appraisal guidance	TBC

Results per page

10
25
50
All